{"url_path":"/sec/cvkd/8-k/2026-07-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1937993/0001213900-26-079824-index.html","accession_number":"0001213900-26-079824","cik":"0001937993","ticker":"CVKD","issuer_name":"Cadrenal Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1937993/0001213900-26-079824-index.html","primary_entity_key":"0001937993","primary_entity_name":"Cadrenal Therapeutics, Inc."},"word_count":50,"has_tables":true,"body_markdown":"** **\n\n**Item\n8.01. Other Events.**\n\n \n\nOn\nJuly 21, 2026, the Company issued a press release announcing a comprehensive alignment of its clinical portfolio into a Cardiac Acute\nCritical Care Franchise and the initiation of a structured process to secure strategic out-licensing, portfolio monetization, or commercial\nco-development partnerships for its late-stage assets."}